Company intelligence / Profile preview

Appello Pharmaceuticals

Nashville, Tennessee, USAappellopharma.com ↗

Ownership: Private
Employees: ~49
Development stage: Phase 1

Overview

Appello Pharmaceuticals is advancing its lead compound AP-472 through clinical trials for Parkinson's disease treatment. The company completed a Phase 1a study where AP-472 was detected in the cerebrospinal fluid of healthy volunteers at levels predicted to be required for efficacy, indicating the drug is brain penetrant. A Phase 1b trial was planned to enroll approximately 20 Parkinson's disease patients with results expected in early 2023.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

AP-472

Partnerships

Vanderbilt University's Warren Center for Neuroscience Drug Discovery (WCNDD)

Beyond the preview

Go deeper on Appello Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Appello Pharmaceuticals.

Explore the full profile